Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. 
Via Benzinga
Exposures COVID-19
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts
BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance. 
Via Investor's Business Daily
Why Is BioNTech Stock Trading Lower On Wednesday?
BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5-€3.1 billion,... 
Via Benzinga
3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50
These dividend stocks selling for under $50 with yields of 5% or more offer a lot to investors at any time making these strong buys. 
Via InvestorPlace
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon. 
Via Benzinga
7 Dangerous Dividend Stocks to Avoid at All Costs: March 2024
Lurking in the weeds like a tiger ready to strike, these dangerous dividend stocks are set to wreak havoc on any investment portfolio. 
Via InvestorPlace
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move
Pfizer just might be one of the biggest comeback stories of the second half of this decade. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These stocks could be cheap only for a season. 
Via The Motley Fool
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues despite promising mechanism of action. Optimism remains for earlier-stage... 
Via Benzinga
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities. 
Via InvestorPlace
Is Pfizer Stock a Millionaire Maker?
A couple of years ago, Pfizer's shares may have seemed like a sure thing. That may not be the case anymore. 
Via The Motley Fool
3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold
If you want to take advantage of the red-hot growth in weight-loss stocks, these are three companies that you can own a piece of today. 
Via InvestorPlace
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer. 
Via The Motley Fool
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga
How To Earn $500 A Month From Pfizer Stock After A Surprise Profit-Turning Quarter
Pfizer Inc. (NYSE: PFE) shares closed slightly higher on Wednesday. 
Via Benzinga
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
Wager on these promising undervalued healthcare stocks, catering to investors aiming to leverage growth within the dynamic healthcare space. 
Via InvestorPlace
Want $2K Per Month in Retirement? Buy These 3 Dividend Stocks Now.
Investors wanting to enjoy some passive income during retirement should invest in these 3 dividend stocks. 
Via InvestorPlace
Topics Retirement
Exposures Pension
3 Stocks I'm Adding to My Retirement Account in March
A handful of names offer a combination of reliability and opportunity that many other stocks don't right now. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Be A Smart Investor – Don’t Hold On For Dear Life
You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months. 
Via Talk Markets
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 
Via InvestorPlace
Will Alphabet 'Storm Back?' Plus: Progressive, D.R. Horton And Pfizer On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. 
Via Benzinga
7 Elite Blue-Chip Stocks Predicted to Double Your Fortune by 2028
Explore three elite blue-chip stocks in interactive media, transaction processing, semiconductors, pharmaceuticals, and telecommunication. 
Via InvestorPlace
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
From Pfizer Inc.
Via Business Wire
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma
Pfizer's Phase 3 study reveals Adcetris combo significantly improves overall survival in relapsed/refractory DLBCL. Positive outcomes in progression-free survival and overall response rate. 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.